Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response.
Makanga DR, Jullien M, David G, Legrand N, Willem C, Dubreuil L, Walencik A, Touzeau C, Gastinne T, Tessoulin B, Le Gouill S, Mahé B, Gagne K, Chevallier P, Clemenceau B, Retière C.
Makanga DR, et al. Among authors: legrand n.
Oncoimmunology. 2021 Jun 14;10(1):1936392. doi: 10.1080/2162402X.2021.1936392.
Oncoimmunology. 2021.
PMID: 34178429
Free PMC article.